For antibiotics, the right dose is restraint

📌 Summary:

• Context: A Lancet Public Health study flags a worrying imbalance in India's antibiotic use — over-reliance on stronger medicines while safer first-line drugs remain underused
• WHO AWaRe classification: 'Access' drugs (first-line for common infections), 'Watch' drugs (broad-spectrum, reserved for specific cases), and 'Reserve' drugs (last line against highly resistant infections)
• Key data: India's optimal use is 9.9–14.7 defined daily doses (DDD) per 1,000 people/day, but actual use is 18.3; 'Watch' antibiotics are at 9.3 DDD (vs recommended 6), while 'Access' drugs at 4.5 DDD fall short
• Causal chain: Broad-spectrum prescriptions feel like reassurance to patients and overstretched doctors, but each unnecessary dose narrows future options; underuse of 'Reserve' drugs in genuinely resistant cases signals the wrong medicine reaching patients
• Systemic drivers: Fragmented healthcare delivery, poor diagnostic access, and liberal antibiotic use in livestock and agriculture all fuel antimicrobial resistance (AMR)
• Solutions: Replace quick-fix prescriptions with evidence-based care; National Action Plan on AMR 2.0 (2025–2029) centres antimicrobial stewardship across human health, animal husbandry and agriculture; stricter compliance across the pharma supply chain to curb OTC sales and irrational fixed-dose combinations

🎯 UPSC Relevance: GS2/GS3 — public health governance, AMR, One Health approach, and drug regulation

📝 Prelims Facts:

• WHO classifies antibiotics under the AWaRe framework: Access, Watch, Reserve
• 'Defined Daily Dose (DDD)' is the standard unit for measuring drug consumption
• India's National Action Plan on AMR 2.0 runs 2025–2029

🔑 Key Term: Antimicrobial Resistance (AMR) — when microbes evolve to resist drugs that once killed them, making infections harder and costlier to treat.